Hong Mei Hua, Sun Hong, Jin Cheng He, Chapman Mark, Hu Junlian, Chang William, Burnett Kelven, Rosen Jon, Negro-Vilar Andres, Miner Jeffrey N
Department of Research and Development, Ligand Pharmaceuticals Inc., 10275 Science Center Drive, San Diego, California 92121, USA.
Endocrinology. 2008 Mar;149(3):1103-12. doi: 10.1210/en.2007-0530. Epub 2007 Dec 6.
Although it is evident that androgens increase muscle mass and strength, little is known about the critical molecular targets of androgens in skeletal muscle. In rodents, the skeletal alpha-actin gene is a tissue-specific gene expressed only in the levator ani and other skeletal muscles but not in the prostate or preputial gland, the well-known androgen target tissue. We identified tissue-specific androgen-regulated genes in the skeletal muscle in rats after oral administration of androgens and focused on androgen-dependent up-regulation of the skeletal alpha-actin gene. To investigate the mechanism of action, an in vitro system with various cell lines and a series of deletion mutants of the alpha-actin promoter were used. The human skeletal alpha-actin promoter was activated by androgens in the muscle cell line C2C12 but not in the liver, prostate, or breast cancer cell lines in which exogenous human androgen receptor is expressed. The sequence of the promoter is sufficient for cell-specific androgen response, providing a model for the tissue specificity demonstrated in vivo. Using a series of deletion mutants, the androgen response can be maintained using just the proximal promoter region. The importance of androgen regulation of this small portion of the human skeletal alpha-actin promoter was demonstrated by the correlation between muscle and the alpha-actin promoter activity for an array of selective androgen receptor modulators (SARMs), including an orally active SARM LGD2226. Taken together, the results suggest that the regulation of skeletal alpha-actin by androgens/SARMs may represent an important model system for understanding androgen anabolic action in the muscle.
虽然雄激素可增加肌肉质量和力量这一点很明显,但对于雄激素在骨骼肌中的关键分子靶点却知之甚少。在啮齿动物中,骨骼肌α-肌动蛋白基因是一种组织特异性基因,仅在提肛肌和其他骨骼肌中表达,而在前列腺或包皮腺(众所周知的雄激素靶组织)中不表达。我们在给大鼠口服雄激素后,鉴定了骨骼肌中组织特异性雄激素调节基因,并聚焦于骨骼肌α-肌动蛋白基因的雄激素依赖性上调。为了研究其作用机制,使用了具有各种细胞系和一系列α-肌动蛋白启动子缺失突变体的体外系统。人骨骼肌α-肌动蛋白启动子在肌肉细胞系C2C12中被雄激素激活,但在表达外源性人雄激素受体的肝癌、前列腺癌或乳腺癌细胞系中未被激活。该启动子序列足以实现细胞特异性雄激素应答,为体内显示的组织特异性提供了一个模型。使用一系列缺失突变体,仅使用近端启动子区域就能维持雄激素应答。包括口服活性选择性雄激素受体调节剂(SARM)LGD2226在内的一系列SARM的肌肉与α-肌动蛋白启动子活性之间的相关性,证明了雄激素对人骨骼肌α-肌动蛋白启动子这一小部分的调节作用的重要性。综上所述,结果表明雄激素/SARM对骨骼肌α-肌动蛋白的调节可能代表了一个理解雄激素在肌肉中合成代谢作用的重要模型系统。